Armando Orlandi: Key predictors of response to chemotherapy-free regimens in HER2+/ER+ breast cancer
Armando Orlandi, Medical Oncologist at Agostino Gemelli University Policlinic, shared an article by Maurizio Callari, et al. on LinkedIn:
“New Study Revolutionizes Treatment Approach for HER2+/ER+ Breast Cancer.
Exciting findings from the NA-PHER2 trial, published in Nature Communications, reveal key predictors of response to chemotherapy-free regimens in HER2+/ER+ breast cancer!
The study examined patients receiving HER2-targeted therapy (trastuzumab + pertuzumab) with CDK4/6 inhibition (palbociclib) +/- endocrine therapy (fulvestrant).
Key findings:
- High immune infiltration and low ER signaling strongly predict complete pathological response
- A simple biomarker combination (ESR1-low/B2M-high) identified patients with a 72.7% pCR rate
- TP53 mutations were associated with early treatment resistance
- Patients can be stratified into distinct response groups with different molecular profiles and prognoses
This groundbreaking research opens the door to precision medicine approaches that may spare selected patients from chemotherapy while identifying those who need alternative treatment strategies.
Looking forward to seeing how these findings translate to clinical practice!
As an oncologist, I’m particularly excited about the potential to offer less toxic treatments to appropriate patients while identifying molecular targets like PAK4 for those with resistant disease.”
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.
Authors: Maurizio Callari, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023